IL160105A0 - Vaccine for treatment of motor neurone diseases - Google Patents
Vaccine for treatment of motor neurone diseasesInfo
- Publication number
- IL160105A0 IL160105A0 IL16010502A IL16010502A IL160105A0 IL 160105 A0 IL160105 A0 IL 160105A0 IL 16010502 A IL16010502 A IL 16010502A IL 16010502 A IL16010502 A IL 16010502A IL 160105 A0 IL160105 A0 IL 160105A0
- Authority
- IL
- Israel
- Prior art keywords
- cop
- vaccine
- treatment
- motor neurone
- tyr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33613901P | 2001-12-06 | 2001-12-06 | |
PCT/IL2002/000979 WO2003047500A2 (fr) | 2001-12-06 | 2002-12-05 | Vaccin et methode de traitement de maladies du motoneurone |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160105A0 true IL160105A0 (en) | 2004-06-20 |
Family
ID=23314742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16010502A IL160105A0 (en) | 2001-12-06 | 2002-12-05 | Vaccine for treatment of motor neurone diseases |
Country Status (24)
Country | Link |
---|---|
US (1) | US7351686B2 (fr) |
EP (1) | EP1429800B1 (fr) |
JP (1) | JP4542339B2 (fr) |
KR (1) | KR20040081431A (fr) |
CN (2) | CN102151330B (fr) |
AT (1) | ATE422362T1 (fr) |
AU (1) | AU2002353486B2 (fr) |
CA (1) | CA2469092C (fr) |
CY (1) | CY1109044T1 (fr) |
DE (1) | DE60231131D1 (fr) |
DK (1) | DK1429800T3 (fr) |
ES (1) | ES2322566T3 (fr) |
HK (1) | HK1067043A1 (fr) |
HU (1) | HU228207B1 (fr) |
IL (1) | IL160105A0 (fr) |
IS (1) | IS2670B (fr) |
MX (1) | MXPA04005537A (fr) |
NO (1) | NO336231B1 (fr) |
NZ (1) | NZ533356A (fr) |
PL (1) | PL205469B1 (fr) |
PT (1) | PT1429800E (fr) |
RU (1) | RU2303996C2 (fr) |
SI (1) | SI1429800T1 (fr) |
WO (1) | WO2003047500A2 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399740B2 (en) | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
ATE548045T1 (de) * | 2003-01-07 | 2012-03-15 | Yeda Res & Dev | Vakzine in augentropfenform enthaltend copolymer 1 für die therapeutische immunisierung |
EP1684797A1 (fr) | 2003-11-12 | 2006-08-02 | Yeda Research and Development Co. Ltd. | Vaccin et procede pour traiter des maladies neurodegeneratives |
JP4808631B2 (ja) | 2003-12-09 | 2011-11-02 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 精神医学的障害の治療用のコポリマー1を含む方法及びワクチン |
CA2558380A1 (fr) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Therapie de combinaison avec acetate de glatiramer et riluzole |
WO2005120542A2 (fr) * | 2004-05-07 | 2005-12-22 | Peptimmune, Inc. | Methodes de traitement de maladie a l'aide de copolymeres aleatoires |
US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
JP5241012B2 (ja) * | 2005-07-15 | 2013-07-17 | ノバルティス アーゲー | Pamps、病原体関連分子パターン |
CN100448481C (zh) * | 2006-06-22 | 2009-01-07 | 中国科学院遗传与发育生物学研究所 | xCT蛋白及其编码基因的新用途 |
WO2009040814A1 (fr) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Utilisation du copolymère 1 pour le traitement de la dystrophie musculaire |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
MX347871B (es) | 2010-10-11 | 2017-05-16 | Teva Pharmaceutical Ind Ltd * | Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. |
ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
EA201490749A1 (ru) | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз Лтд. | Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат |
US9861686B2 (en) * | 2011-12-05 | 2018-01-09 | Ben-Gurion University Of The Negev Research & Development Authority | Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS) |
CA2907909A1 (fr) * | 2012-03-26 | 2013-10-03 | Neuroquest Ltd. | Marqueurs cellulaires pour diagnostiquer la maladie d'alzheimer et la progression de la maladie d'alzheimer |
WO2014037952A1 (fr) | 2012-09-10 | 2014-03-13 | Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science | Thérapie d'immunomodulation individualisée pour des troubles neurodégénératifs, une lésion du snc et la démence liée à l'âge |
MX2019010174A (es) | 2017-03-26 | 2019-10-15 | Mapi Pharma Ltd | Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
US3849650A (en) | 1973-03-29 | 1974-11-19 | Picker Corp | Automatic x-ray inspection system |
US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
SE505316C2 (sv) | 1995-10-17 | 1997-08-04 | Kenneth G Haglid | Användning av proteinet S-100b för framställning av läkemedel för nervceller |
US20030108528A1 (en) | 1998-05-19 | 2003-06-12 | Michal Eisenbach-Schwartz | Activated t-cells, nervous system-specific antigens and their uses |
US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
CA2328612A1 (fr) | 1998-05-19 | 1999-11-25 | Yeda Research And Development Co., Ltd. | Lymphocytes t actives, antigenes specifiques du systeme nerveux et leur utilisation |
JP2002500199A (ja) | 1998-07-21 | 2002-01-08 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 活性化t細胞、及びそれらの用途 |
WO2000005249A2 (fr) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes |
ES2243450T3 (es) * | 2000-01-20 | 2005-12-01 | Yeda Research And Development Co. Ltd. | El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para terapia neuroprotectora. |
US20020037848A1 (en) * | 2000-06-07 | 2002-03-28 | Michal Eisenbach-Schwartz | Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
WO2002076503A1 (fr) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere |
US7399740B2 (en) * | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
US6835711B2 (en) * | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
-
2002
- 2002-12-05 EP EP02788511A patent/EP1429800B1/fr not_active Expired - Lifetime
- 2002-12-05 CN CN201110056639.8A patent/CN102151330B/zh not_active Expired - Fee Related
- 2002-12-05 HU HU0500039A patent/HU228207B1/hu not_active IP Right Cessation
- 2002-12-05 DK DK02788511T patent/DK1429800T3/da active
- 2002-12-05 US US10/485,576 patent/US7351686B2/en not_active Expired - Lifetime
- 2002-12-05 CN CNA028277015A patent/CN1617736A/zh active Pending
- 2002-12-05 PL PL370070A patent/PL205469B1/pl unknown
- 2002-12-05 DE DE60231131T patent/DE60231131D1/de not_active Expired - Lifetime
- 2002-12-05 RU RU2004120536/14A patent/RU2303996C2/ru not_active IP Right Cessation
- 2002-12-05 AT AT02788511T patent/ATE422362T1/de active
- 2002-12-05 AU AU2002353486A patent/AU2002353486B2/en not_active Ceased
- 2002-12-05 SI SI200230800T patent/SI1429800T1/sl unknown
- 2002-12-05 ES ES02788511T patent/ES2322566T3/es not_active Expired - Lifetime
- 2002-12-05 KR KR10-2004-7008780A patent/KR20040081431A/ko active Search and Examination
- 2002-12-05 WO PCT/IL2002/000979 patent/WO2003047500A2/fr active Application Filing
- 2002-12-05 JP JP2003548761A patent/JP4542339B2/ja not_active Expired - Fee Related
- 2002-12-05 MX MXPA04005537A patent/MXPA04005537A/es active IP Right Grant
- 2002-12-05 IL IL16010502A patent/IL160105A0/xx unknown
- 2002-12-05 PT PT02788511T patent/PT1429800E/pt unknown
- 2002-12-05 NZ NZ533356A patent/NZ533356A/en not_active IP Right Cessation
- 2002-12-05 CA CA2469092A patent/CA2469092C/fr not_active Expired - Fee Related
-
2004
- 2004-06-03 IS IS7296A patent/IS2670B/is unknown
- 2004-07-05 NO NO20042833A patent/NO336231B1/no not_active IP Right Cessation
- 2004-12-16 HK HK04110020.9A patent/HK1067043A1/xx not_active IP Right Cessation
-
2009
- 2009-05-06 CY CY20091100485T patent/CY1109044T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL160105A0 (en) | Vaccine for treatment of motor neurone diseases | |
AU6185398A (en) | Charged lipids and uses for the same | |
EA200601132A1 (ru) | Предупреждение и лечение амилоидогенного заболевания | |
HUP0401568A2 (hu) | Periokuláris vagy subconjunctivális adagolásra alkalmas szemészeti depó készítmények | |
AU6762794A (en) | A coagulation factor viii formulation | |
WO2002100390A3 (fr) | Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain | |
UA88270C2 (ru) | Фармацевтический препарат и его применение для профилактики удара, диабета | |
TW200509968A (en) | Prevention and treatment of synucleinopathic disease | |
MA28149A1 (fr) | Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine | |
HK1049444A1 (en) | Transdermal therapeutic system for parkingson's disease inducing high plasma levels of rotigotine | |
IL110045A0 (en) | Pharmaceutical compositions containing oligopeptides combating aids and arc and for immune stimulation and certain such novel oligopeptides | |
HK1029043A1 (en) | Remedy for neurodegenerative diseases. | |
CA2299361A1 (fr) | Utilisation d'un interferon consensus en combinaison avec l'antagoniste du recepteur de l'il-1 pour traiter les patients atteints de sclerose en plaques | |
MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
NZ516477A (en) | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders | |
AU7242796A (en) | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
MXPA02005563A (es) | Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma. | |
CA2225788A1 (fr) | Agents therapeutiques pour maladies auto-immunes | |
MXPA02011533A (es) | Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona. | |
NZ505538A (en) | A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma | |
YU45103A (sh) | Upotreba sarp/1 za lečenje i prevenciju skleroderme | |
CA2414586A1 (fr) | Agent de traitement therapeutique des maladies du nerf optique et de maladies semblables | |
WO2003026570A3 (fr) | Formulations de cisplatine a toxicite reduite et leurs procedes d'utilisation | |
GB2407321A (en) | Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor |